Net spending on biologics totaled $125.5 billion in last year, up 9.5% since 2017. Biosimilar spending has doubled since 2017 but still represents under 2% of the total US biologics market. Biosimilars are used less than one-third of the time, a recent report from IQVIA said.
A recent report from IQVIA looking ahead to 2023 forecasts that US net medicine spending will increase from $344 billion in 2018 to $420 billion, an aggregate growth of $76 billion, driven by new brands, which are expected to add $73 billion of new spending.
However, that will be offset by brands losing exclusivity, forecast to total $78 billion in savings over the next 5 years, the report said.
The report, titled “Medicine Use and Spending in the US,” said average brand net price changes for protected branded drugs are predicted to fall between 1% and increase to 2% per year through 2023, resulting in about $12 billion in incremental spending.
Over the next 5 years, the $105 billion impact of losses of exclusivity are expected to be 46% greater, including biosimilars, at the invoice price level (invoice-based pricing is derived from IQVIA proprietary information gathered from wholesalers and company direct sales. It includes some price concessions, but not all of them). The report said growth won’t be greater than the combined growth from new brands and volume growth for existing brands.
Patent expirations will increase over the next 5 years, peaking in 2023. Protected brands, including AbbVie’s Humira, will lose $33 billion.
2018 Spending on Biosimilars
Net spending on biologics totaled $125.5 billion in last year, up 9.5% since 2017. Biosimilar spending has doubled since 2017 but still represents under 2% of the total US biologics market. Biosimilars are used less than one-third of the time, the report said.
Looking back to 2018, the report said biosimilars as well as generics had modest growth in volume. The biosimilar share of volume exceeded 30% for those medicines, but in total these medicines represent less than 1% of biologic volume.
Total biologics spending grew by 9.5% last year; 13% of the spending in the market is now subject to biosimilar competition, where biosimilars have captured about 12% of total available spend.
Autoimmune Trends by Treatment Area
Last year, autoimmune prescriptions increased at a 5-year compound annual growth rate (CAGR) of 9%, while patient volume had a 10.2% CAGR; the report said that indicates new patients are being treated, but overall rates of adherence are relatively unchanged.
The number of autoimmune patients being treated is up 63% since 2013, with 6 million more patients per year receiving therapy, largely driven by new treatments for psoriasis and related conditions. In 2018 alone, the number of autoimmune patients being treated grew by 20%.
Rheumatoid arthritis (RA) continues to be the most common autoimmune disease treated, with 41% of all autoimmune patients treated for the condition in 2018. However, this is a decrease from 48% in 2013; IQCVIA said this indicates the emergence of effective therapies for other autoimmune conditions.
Ulcerative colitis (UC) and psoriasis grew the most last year (29% and 30%, respectively), while Crohn disease (CD), psoriatic arthritis, and ankylosing spondylitis increased by 27%, 23%, and 21%, respectively.
Areas of high unmet need, such as CD and UC, both areas of high unmet need, saw a doubling (195%) and tripling (292%) of patients treated since 2013, respectively.
Psoriasis and psoriatic arthritis-treated patient populations both more than doubled, increasing by 120% since 2013. Psoriasis and psoriatic arthritis now comprise 18% and 11% of treated patients, respectively.
Specialty Medicines
Overall, 127 million specialty prescriptions were dispensed in retail and mail pharmacies in 2018, up by 15 million since 2014.
Specialty medicine prescriptions grew by over 5%, even as those medicines account for only 2.2% of prescriptions and have little impact on the overall growth of dispensed prescriptions. Net spending on specialty medicines increased 5.8% on a per capita basis, while traditional medicine costs fell 3.4%.
Prescriptions for chronic diseases account for more than two-thirds of prescriptions, and the increasing use of 90-day prescriptions means patients have significantly more medicine on hand.
Overcoming Challenges to Improve Access and Reduce Costs
November 12th 2024Biosimilars hold the potential to dramatically lower health care costs and improve access to life-changing treatments, but realizing this potential will require urgent policy reforms, market competition, and better education for both providers and patients.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Skyrizi Overtakes Humira: “Product Hopping” Leaves Biosimilar Market in Limbo
November 7th 2024For the first time, Skyrizi (risankizumab-rzaa) has replaced Humira (reference adalimumab) as AbbVie’s sales driver, largely due to companies encouraging “product hopping” to avoid competition, creating concerns for the sustainability of the burgeoning adalimumab biosimilar market.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Panelists Stress Stakeholder Education to Build Confidence in Biosimilars
October 31st 2024By expanding educational initiatives to clarify biosimilar safety, efficacy, and interchangeability, stakeholders can foster trust, improve access, and ensure that biosimilars are widely accepted as high-quality, cost-effective alternatives to originator biologics.